Boston Scientific Finally Beats MRI-Compatibility Challenges In Spinal Cord Stim
This article was originally published in The Gray Sheet
Executive Summary
The firm's Precision Montage MRI spinal cord stimulator passed FDA muster 12 years after Boston Scientific's original platform SCS device reached the market.
You may also be interested in...
Market Intel: Pain Management II: Competition Intensifies For Spinal Cord Stim Market's Big Three
In the global pain management market, spinal cord stimulation (SCS) systems are expected to continue to be the fastest-growing segment with increasing competition among device manufacturers to develop innovative, targeted therapies. In this second article of a two-part series, we'll discuss the competitive landscape in the SCS market, the key players, emerging companies and their respective technologies.
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.